Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma

Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma

Abstract Precision medicine in hepatocellular carcinoma (HCC) relies on validated biomarkers that help subgroup patients for targeted treatment. Here, we identified a novel candidate oncogene, ribosomal protein L22-like1 (RPL22L1), which was markedly elevated in HCC, contributed to HCC malignancy an...

Full description

Bibliographic Details
Main Authors: Dongmei Zhang, Yunzhen Zhou, Yanan Ma, Ping Jiang, Hongchao Lv, Sijia Liu, Yu Mu, Chong Zhou, Shan Xiao, Guohua Ji, Peng Liu, Ning Zhang, Donglin Sun, Haiming Sun, Nan Wu, Yan Jin
Format: Article
Language:English
Published: Nature Publishing Group 2022-08-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-022-01153-8

Internet

https://doi.org/10.1038/s41420-022-01153-8

Similar Items